ScarDx One-Pager

One-liner: ScarDx is transforming organ scarring diagnosis with innovative AI imaging solutions that improve patient outcomes and streamline clinical trials.

Problem: Organ fibrosis (scarring) drives chronic kidney disease and liver cirrhosis, impacting over 2 billion people globally. Current diagnostics (biopsies) are invasive, risky, costly, and prone to sampling errors. Pharmaceutical companies struggle to evaluate relevant therapies efficiently with existing diagnosis tools.

Target User:

- **Clinicians:** Real-time, holistic fibrosis measurement with existing equipment.
- **Pharmaceuticals:** Companion diagnostic tool enabling faster, cost-effective trials.
- **Ultrasound Manufacturers:** Enhanced device functionality for new revenue streams.

Solution / Product: ScarDx H-Scan Technology converts raw ultrasound data into real-time, high-resolution fibrosis measurements using artificial intelligence. It works with any standard ultrasound probe, enabling immediate use and scalability. The technology is non-invasive, accurate, and cost-effective, serving as a viable alternative to biopsies.

Revenue Model:

- **Manufacturers Sub-Licensing Fee:** Ultrasound manufacturers pay a sub-licensing fee to install ScarDx capabilities into their products at an increased price.
- **SaaS Fee:** Clinicians and pharmaceutical companies pay a monthly SaaS fee to ScarDx directly to utilize the software.

Moat / Tech Edge: The proprietary AI-driven H-Scan technology, combined with its ability to integrate with standard ultrasound probes, provides a significant technological edge. The existing model has been trained on data from world-leading healthcare institutions, enhancing its accuracy and reliability.

Market Thesis: The urgent demand for non-invasive, accurate fibrosis diagnostics, coupled with the growing adoption of portable ultrasound devices in clinics and innovations in AI and imaging, positions ScarDx for significant market penetration. The global market for fibrosis diagnostics is substantial, with 2.3 billion people affected by chronic diseases like CKD and liver cirrhosis.